Kenvue Inc. (NYSE:KVUE) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have been assigned an average rating of “Hold” from the fifteen brokerages that are currently covering the company, Marketbeat reports. Twelve research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $19.2727.

A number of brokerages have commented on KVUE. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Barclays boosted their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Finally, Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th.

Kenvue Stock Up 0.1%

KVUE opened at $17.77 on Friday. Kenvue has a one year low of $14.02 and a one year high of $20.13. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The stock has a market capitalization of $34.14 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 1.58 and a beta of 0.46. The business’s 50-day simple moving average is $19.09 and its 200-day simple moving average is $18.24.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.29 earnings per share. Analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 2nd. Investors of record on Monday, September 21st will be paid a $0.21 dividend. The ex-dividend date is Monday, September 21st. This represents a $0.84 annualized dividend and a dividend yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is 96.55%.

Institutional Trading of Kenvue

A number of institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Kenvue in the 2nd quarter worth about $2,882,279,000. California State Teachers Retirement System increased its holdings in Kenvue by 1,695.1% during the 2nd quarter. California State Teachers Retirement System now owns 56,438,843 shares of the company’s stock valued at $1,078,546,000 after acquiring an additional 53,294,807 shares in the last quarter. Pentwater Capital Management LP acquired a new position in Kenvue during the second quarter worth about $977,094,000. Norges Bank purchased a new stake in shares of Kenvue in the fourth quarter valued at about $756,862,000. Finally, Independent Franchise Partners LLP lifted its holdings in shares of Kenvue by 56.3% in the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after purchasing an additional 17,343,785 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health.